Related Experiment Video
Updated: Jan 16, 2026
Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
Published on: August 2, 2024
Investigating the effects of miR-526b and miR-655 on doxorubicin sensitivity in breast cancer
Reid Morgan Opperman1, Sujit Maiti1, Mousumi Majumder2
1Department of Biology, John R. Brodie Science Centre, Brandon University, 270 18th Street, Brandon, MB, R7A6A9, Canada.
Abstract:
Doxorubicin is an effective treatment for breast cancer, but drug resistance poses a significant challenge. Emerging regulators of drug resistance include microRNAs, small non-coding RNAs. Two miRNAs, miR-526b and miR-655, promote aggressive breast cancer phenotypes like cell proliferation, cancer stem cell upregulation, altered response to oxidative and metabolic stress and help tumor metastasis by activating COX-2/EP4/PI3K pathways. However, their impact on the effects of chemotherapeutic treatments remains unexplored. This study investigates the impact of overexpressing miR-526b and miR-655 on doxorubicin responses in breast cancer, focusing on pro-survival, apoptotic, and DNA-damage response pathways. We confirm the role of PI3K/Akt signalling in promoting cell survival and resistance in response to doxorubicin in vitro, though key differences exist between each cell line. High-throughput analysis of doxorubicin-exposed breast cancer cell lines, revealing novel mechanisms of miR-526b and miR-655. Overexpression of miR-526b and miR-655 may alter doxorubicin efficacy through mechanisms like DNA damage response changes, metabolic reprogramming, and immune pathway activation. Further investigation may uncover new therapeutic strategies to improve treatment efficacy and patient outcomes.
Insights
Two microRNAs, miR-526b and miR-655, may impact breast cancer drug resistance. Their overexpression could alter doxorubicin efficacy by affecting DNA damage, metabolism, and immune pathways, offering potential new therapeutic strategies.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Doxorubicin is a key breast cancer treatment, but drug resistance limits its effectiveness.
- MicroRNAs (miRNAs) are emerging regulators of drug resistance.
- miR-526b and miR-655 are implicated in aggressive breast cancer phenotypes and metastasis via COX-2/EP4/PI3K pathways.
Purpose of the Study:
- To investigate the impact of overexpressing miR-526b and miR-655 on doxorubicin response in breast cancer.
- To focus on pro-survival, apoptotic, and DNA-damage response pathways.
- To explore novel mechanisms of these miRNAs in doxorubicin-treated breast cancer cells.
Main Methods:
- Overexpression of miR-526b and miR-655 in breast cancer cell lines.
- In vitro analysis of doxorubicin response, including cell survival, apoptosis, and DNA damage.
- High-throughput analysis of doxorubicin-exposed cell lines.
Main Results:
- PI3K/Akt signaling confirmed to promote cell survival and doxorubicin resistance in vitro, with cell-line-specific differences.
- Novel mechanisms of miR-526b and miR-655 identified in doxorubicin-exposed breast cancer cells.
- Overexpression of these miRNAs may alter doxorubicin efficacy through DNA damage response, metabolic reprogramming, and immune activation.
Conclusions:
- miR-526b and miR-655 overexpression may influence doxorubicin efficacy in breast cancer.
- Potential mechanisms include modulation of DNA damage response, metabolic pathways, and immune activation.
- Further research could lead to novel therapeutic strategies for improving breast cancer treatment outcomes.
